NCT02226198 - A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Homozygous Familial Hypercholesterolemia (HoFH)

Interventions

DRUG

Rosuvastatin 20mg

Active drug will be taken taken orally, QD, either in the morning or in the evening

DRUG

Placebo

Will be taken taken orally, QD, either in the morning or in the evening

Trial Locations (9)

Research Site, Brussels (Woluwé-St-Lambert)

Research Site, Chicoutimi

Research Site, København Ø

Research Site, Haifa

Research Site, Kuala Lumpur

Research Site, Kubang Kerian

Research Site, Amsterdam

Research Site, Goteborg

Research Site, Taipei